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Abstract
Objective—Preclinical Alzheimer’s disease (AD) defined by a positive AD biomarker in the 
presence of normal cognition is presumed to precede mild cognitive impairment (MCI). Subtle 
cognitive deficits and cognitive inefficiencies in preclinical AD may be detected through process 
and error scores on neuropsychological tests in those at risk for progression to MCI.
Methods—Cognitively normal participants (n=525) from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) were followed for up to five years and classified as either “stable normal” 
(n=305) or “progressed-to-MCI” (n=220). Cox regressions were used to determine if baseline 
process scores on the Rey Auditory Verbal Learning Test (AVLT) (intrusion errors, learning slope, 
proactive interference, retroactive interference) predicted progression to MCI and a CDR score of 
1 after considering demographic characteristics, APOE ε4 status, cerebrospinal fluid AD 
biomarkers, ischemia risk, mood, functional difficulty, and standard neuropsychological total test 
scores for the model.
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Results—Baseline AVLT intrusion errors predicted progression to MCI (HR: 1.04, 95% CI: 
1.01–1.07, p=.008) and improved model fit after the other valuable predictors were already in the 
model, χ2(df=1)=6.330, p=.012. AVLT intrusion errors also predicted progression to CDR = 1 
(HR: 1.10, 95% CI: 1.02–1.18, p=.016) and again improved model fit, χ2(df=1)=4.682, p=.030.
Conclusions—Intrusion errors on the AVLT contribute unique value for predicting progression 
from normal cognition to MCI and normal cognition to mild dementia (CDR=1). Intrusion errors 
appear to reflect subtle change and inefficiencies in cognition that precede impairment detected by 
neuropsychological total scores.
Keywords
Process scores; Intrusion errors; preclinical AD; MCI; subtle cognitive decline
Introduction
According to NIA-AA guidelines (Sperling et al., 2011), objective changes in cognition 
during preclinical Alzheimer’s disease (AD) do not occur until Stage 3 and invariably follow 
amyloidosis (Stage 1) and neurodegeneration (Stage 2). However, recent evidence suggests 
that this proposed temporal sequence is not invariant. Cognitively normal elderly 
participants who progressed to mild cognitive impairment (MCI) in the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) study were more likely to have neurodegeneration than 
amyloidosis as their first indication of preclinical AD. Furthermore, they were just as likely 
to have operationally-defined subtle cognitive decline as amyloidosis as their first indication 
(Edmonds et al., 2015a). These findings indicate that measures of subtle cognitive change 
can be as important as other markers of preclinical AD and suggest that additional research 
is needed to identify the most sensitive and specific cognitive measures that can be used with 
other AD biomarkers (e.g., β-amyloid, tau/hyperphosporylated-tau) to detect preclinical 
disease.
It is well established that memory impairment characterized by rapid forgetting over a delay 
interval is one of the most sensitive indicators of early AD (e.g. Delis et al., 1991, Welsh et 
al., 1991). However, there is evidence that additional process features of performance on 
tests of learning and memory may provide useful information about early cognitive changes 
related to AD (e.g., Libon et al., 2011; Loewenstein et al., 2004).
Analysis of these process scores (i.e., behavior that speak to the errors and process by which 
a test score is achieved), largely advanced by Kaplan (1988) and her colleagues (e.g., Delis, 
Kramer, Kaplan, E., & Ober., 2000; Lamar et al, 2010; Price et al., 2009), emphasize the 
importance of understanding the underlying nature of the brain-behavior interaction that 
leads to a specific outcome or achievement such as the total score on a neuropsychological 
measure. Process analysis of serial word-list learning and memory has been applied to AD 
(e.g., Cahn et al., 1997; Davis et al., 2002; Delis et al., 1991; Libon et al., 1996; Loewenstein 
et al., 2004), subcortical dementias (e.g., Massman, Delis, Butters, Levin & Salmon, 1990), 
and MCI (e.g., Libon et al., 2011). In addition, early AD is associated with abnormally slow 
learning across trials of a word-list memory task (i.e., a flattened learning slope), increased 
susceptibility to interference, and a greater frequency of extra-list intrusion errors (Cahn et 
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al., 1997; Delis et a., 1991; Price et al., 2011; Loewenstein et al., 2004; Salmon & Bondi, 
2009). Similar process features have been observed in the word-list memory test 
performance of patients with amnestic MCI, including rapid forgetting, increased production 
of intrusion errors, and an increased tendency to endorse foils on a recognition measure 
(Libon et al., 2011).
Only a few studies have examined process scores on word-list memory test performance and 
error profiles in cognitively normal older adults or those with preclinical AD. Bondi and 
colleagues (Bondi et al., 1994) found that non-demented older adults with a family history 
of AD had worse recall across learning trials and, after a delay interval, exhibited a greater 
“recency” effect (i.e., a tendency to recall words from the end of a list), and made more 
intrusion errors than those without a family history. Another study showed that delayed free 
recall and cued-recall intrusion errors from a word-list learning test, and apolipoprotein E 
(APOE) ε4 genotype, all significantly and independently predicted progression to AD in 
cognitively normal older adults (Bondi et al., 1999). Mistridis and colleagues (Mistridis, 
Krumm, Monsch, Berres, & Taylor, 2015) found more rapid forgetting (i.e. worse savings 
scores), poorer recognition discriminability, and more intrusion errors on a word-list 
memory task in cognitively normal older adults who later developed MCI compared to those 
who remained normal. In their study, faster forgetting emerged 8 years prior to the diagnosis 
of MCI, while poorer recognition discriminability and more intrusion errors became 
apparent 2 years prior to the MCI diagnosis.
The results of these studies suggest that process and error scores from word-list memory 
measures may be useful for identifying cognitive difficulty or inefficiency in preclinical AD 
prior to the emergence of frank impairment on neuropsychological total scores. To examine 
this possibility, the present study determined the added value of word-list memory test 
process scores to standard neuropsychological total scores, cerebrospinal fluid (CSF) AD 
biomarkers (β-amyloid, tau, hyperphosporylated-tau), and genetic susceptibility for 
predicting progression from cognitively normal to MCI over a 5-year period. The inclusion 
of CSF biomarkers is particularly innovative since these biomarkers are the basis for the 
working definition of preclinical AD (Sperling et al., 2011), and to our knowledge, this is the 
first study to examine neuropsychological process scores as predictors of progression to 
MCI after controlling for these CSF markers. Reliable identification of persons at risk for 
AD will allow greater opportunity to intervene earlier to prevent or delay future decline.
Methods
Procedure
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test 
whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), 
other biological markers, and clinical and neuropsychological assessment can be combined 
to measure the progression of MCI and early AD. For up-to-date information on ADNI, see 
www.adni-info.org. This study was approved by the Institutional Review Boards at each of 
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the participating institutions, and written informed consent was obtained from all 
participants or authorized representatives at each site.
Participants
ADNI participants were between ages 55 and 90 years old, were on stable permitted 
medications, completed at least 6 years of education or work history equivalent, were fluent 
in English or Spanish, had a reliable study partner, had a Geriatric Depression Scale < 6, a 
Hachinski Ischemic Score ≤ 4, adequate visual/auditory acuity, and good general health. 
Participants were excluded at enrollment if they had a history of significant head trauma or 
neurologic disease.
All non-demented ADNI participants were reclassified as “normal” or MCI based on 
application of Jak and Bondi’s actuarial neuropsychological criteria (Bondi et al., 2014; Jak 
et al., 2009) to their baseline data.1 Participants were classified as MCI if (1) they had an 
impaired score, defined as >1 standard deviation (SD) below the age/education/gender-
corrected normative mean on two measures within at least one cognitive domain [memory 
(Rey Auditory Verbal Learning Test delayed recall and recognition), language (category 
fluency and 30-item Boston naming Test), or processing speed/executive function (Trail 
Making Test Parts A and B]; or (2) they had one impaired score, defined as >1 SD below the 
age/education/gender-corrected normative mean, across all three cognitive domains sampled; 
or (3) they were rated by an informant to have a Functional Activities Questionnaire score of 
≥ 6. If none of these criteria were met, the participant was diagnosed as cognitively normal.
This procedure identified 754 cognitively normal participants (at baseline) who were 
considered for inclusion in the current study. Of these participants, 201 were excluded 
because of missing CSF biomarkers, genetic testing or other baseline variables, and 28 were 
excluded for no follow-up data, and, therefore, no opportunity to assess for progression to 
MCI. A final analytic sample of 525 cognitively normal participants was used in the primary 
analyses. The Jak and Bondi actuarial neuropsychological MCI criteria were then applied to 
data collected at the 6-, 12-, 24-, 36-, 48-, and 60-month follow-up visits to determine which 
of these 525 participants progressed to MCI within 5 years of baseline. Based on this 
determination, participants were classified as “Stable normal” (n=305) or “progressed to 
MCI” (n=220). Table 1 presents baseline demographic and clinical characteristics for the 
entire sample and separately for the stable normal and progressed-to-MCI groups. The 229 
excluded participants were older [t(751)=3.65, p<.001, d=.29], slower on the Trail Making 
Test, Part A [t(751)=2.39, p=.017, d=.19], and had a flatter Rey Auditory Verbal Learning 
Test learning slope [t(751)=−2.44, p=.015, d=.19] than the 525 included participants, but did 
not differ on any other demographic, clinical, biomarker, or cognitive variables. Because the 
majority of excluded participants were excluded due to missing CSF data (n=191), a follow 
up analysis was run that included all participants with baseline neuropsychological data and 
1The Jak and Bondi actuarial neuropsychological MCI criteria were applied because they more accurately diagnose MCI than the 
original ADNI criteria (Bondi et al., 2014). The original ADNI criteria are susceptible to false-positive (i.e., participants diagnosed as 
MCI but had normal cognitive and biomarker profiles, normal cortical thickness maps, normal amyloid imaging levels, and lower rates 
of decline; Bangen et al., 2016; Bondi et al., 2014, Edmonds et al., 2015b, 2016a) and false-negative (i.e., participants diagnosed as 
normal but had impaired cognitive scores, abnormal biomarkers, and rates of progression consistent with MCI; Edmonds et al., 2016b) 
diagnostic errors.
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with at least one follow up visit (n=716) to determine whether the inclusion of these 
participants changed the pattern of process score effects.
Of the 525 participants included in the primary analysis, all participants had a baseline CDR 
score of 0 or 0.5; within 5 years, 22 progressed to a Clinical Dementia Rating (CDR) = 1, 
which is consistent with a mild dementia classification (Burke et al., 1988; Morris, 1993). A 
secondary analysis examining time to progression to CDR = 1 was used to support the 
primary findings related to progression to MCI.
Measures
Depression and Functional Impairment—The Geriatric Depression Scale (GDS; 
Sheikh & Yesavage, 1986) was used to assess depressive symptomatology. Higher scores 
indicate more depressive symptoms. The informant-rated Functional Activities 
Questionnaire (FAQ; Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982) was used to measure 
difficulty with daily activities (e.g., paying bills, remembering appointments, shopping). 
Higher scores indicate more functional difficulty. The CDR (Morris, 1993) is based on 
informant and participant interviews that assess cognitively-driven functional change. Scores 
are independent of neuropsychological measures and a CDR score of 1 correspond a 
classification of mild dementia. The CDR was not used in participant diagnostic 
classification, but was used as an independent validation of the primary analysis results.
Biological Markers of AD—CSF concentrations of β-amyloid (Aβ1–42), total tau (t-tau), 
and hyperphosporylated-tau (p-tau181p) were used to assess AD pathology. Lower CSF 
levels of Aβ1–42 and higher levels of p-tau181p and t-tau are indicative of greater AD 
pathology in the brain. APOE ε4 status was included as a dichotomous variable of genetic 
AD susceptibility. APOE ε4 positivity is related to a higher rate of development of AD (e.g., 
Bondi et al., 1995). A modified Hachinski score (Rosen, Terry, Fuld, Katzman, & Peck, 
1980) was used to quantify ischemia risk.
Neuropsychological Total Scores—Total scores from standard neuropsychological 
tests included: (1) free recall across Trials 1–5 on the Rey Auditory Verbal Learning Test 
(AVLT; Rey, 1964); (2) 30-minute delayed free recall on the Rey AVLT; (3) correct 
responses on the Animal Fluency test; (4) correct responses (spontaneous and with semantic 
cues) on the 30-item Boston Naming Test (BNT); (5) time (seconds) to complete the Trail 
Making Test (TMT) Part A; and (6) time (seconds) to complete the TMT Part B.
AVLT Process Scores—The Rey AVLT is a 15-item word-list learning and memory test 
that includes 5 learning trials with auditory presentation of the 15 words and immediate 
recall on each trial (List A Trials 1–5), an interference trial with a different list of words 
(List B), a short-delay free recall trial for List A words immediately after List B (Trial 6), a 
long delay free recall trial for List A words after 30-minutes of unrelated testing (Trial 7), 
and delayed recognition of List A words presented among an equal number of new distractor 
words. Four process scores from the Rey AVLT were used in the present analyses. An 
intrusion errors score was calculated as the total number of intrusion errors across all 
immediate (List A Trials 1–5, List B) and delayed free recall (short- and long-delay) trials. 
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An intrusion was defined as the production of any word that was not on the list that was 
being recalled (i.e., extra-list). A learning score was calculated as (List A Trial 5 – List A 
Trial 1)/5. This measure provides an estimate of the learning slope across trials. A larger 
score indicates faster learning. A proactive interference score was calculated as List B/Mean 
of List A Trials 1–5 (Loewenstein et al., 2004). A lower score indicates greater susceptibility 
to proactive interference (i.e., previous learning inhibits new learning). A retroactive 
interference score was calculated as List A Trial 6/List A Trial 5 (Loewenstein et al., 2004). 
A lower score indicates greater susceptibility to retroactive interference (i.e., new learning 
inhibits recall of previously learned information).
Statistical Analyses
Baseline demographic and clinical characteristics for each group (i.e., stable normal or 
progressed-to-MCI) were examined using independent samples t-tests for normally 
distributed variables, Mann-Whitney U tests for non-normally distributed variables, or chi-
squared tests for categorical variables.
Progression to MCI—The primary analyses used Cox proportional hazards models to 
examine the predictors of time to MCI diagnosis. Specifically, the four models were run to 
examine the added predictive value of the individual process score variables (Model 1: 
intrusion errors, Model 2: learning slope, Model 3: proactive interference, Model 4: 
retroactive interference) after other relevant variables were already included in the model. 
Because raw data were used for the analyses, demographic variables (age, education, sex) 
were entered in Block 1. Then, GDS, FAQ, Hachinski score, APOE ε4 status, p-tau, t-tau, β-
amyloid, category fluency, BNT, Trails A, Trails B, AVLT immediate recall, and AVLT 
delayed recall were considered for Block 2 and a forward stepwise procedure was used to 
determine which of these variables were included in the model so that only predictors that 
add value were included. Block 3 included the individual process score to determine whether 
the model fit was improved with the addition of this variable. Model fit was evaluated with 
the change in log-likelihood (i.e., −2LL) using a chi-square test to compare the change in fit 
with the addition of the third block that included the process score.
In these analyses, time-to-MCI was the number of months from the initial 
neuropsychological assessment to the neuropsychological assessment when they first met 
criteria for MCI. Participants who did not progress to MCI during their follow-up period 
were censored at their last occasion. Multicollinearity of the independent variables was 
assessed and all variance inflation factor (VIF) values were less than 3. The model was also 
run with all variables entered in the model (rather than using a stepwise approach for Block 
2) and the pattern of process score results did not differ, so the more parsimonious stepwise 
approach was reported.
Follow-up analyses were then conducted to determine whether the effect of the process 
scores was different when the CSF variables (p-tau, t-tau, β-amyloid) were excluded from 
the model, allowing for a larger sample size. The 4 models described above were replicated 
without the CSF variables.
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Progression to CDR=1—Secondary Cox models were used to examine the predictors of 
time to CDR = 1. The same approach as described above for the time-to-MCI analyses were 
completed, including the forward stepwise approach for block 2, which lead to slightly 
different predictors in the model.
For process scores that added significant predictive value for progression, Kaplan-Meier 
curves were used to obtain a graphical display. The continuous process score variables were 
re-coded into categorical variables for the Kaplan-Meier curves such that −1 SD and below 
the mean was coded as 0, −1 to +1 SD was coded as 1, and +1 SD and above was coded as 
2. The ±1 SD criteria were used to be largely consistent with the 1 SD cutoffs that are used 
in the MCI criteria. A Log Rank test was used to determine if there were significant 
differences between the categorical process score variables.
Results
Results of the baseline comparisons between participants who remained cognitively normal 
versus those who progressed to MCI within 5 years are shown in Table 1. Compared to those 
who remained cognitively normal, participants who progressed to MCI were more likely to 
be older, male, had more depressive symptoms, had more functional difficulty, were more 
likely to be an APOE ε4 carrier, had higher CSF t-tau levels, lower CSF β-amyloid levels, 
poorer performance on all neuropsychological total scores (AVLT immediate and delayed 
recall, category fluency, BNT, TMT Part A and Part B), more AVLT intrusion errors, a 
shallower learning slope on AVLT Trials 1–5, and greater AVLT retroactive interference 
(i.e., less recall after AVLT List B as a proportion of Trial 5 recall).
Progression to MCI
The results of the Cox models examining the predictors of time to MCI are shown in Table 
2. Blocks 1 and 2 (Block 1: demographics; Block 2: stepwise predictors) were the same 
across the four models. For Block 2, the forward stepwise procedure included the following 
variables: FAQ, category fluency, BNT, AVLT delayed recall, APOE ε4 status, and t-tau. 
Blocks 1 and 2 showed significant incremental improvement in model fit: Block 1 
χ2(3)=9.23, p<.026 and Block 2 χ2(6)=153.37, p<.001.
With the addition of intrusion errors (Block 3), there was a significant incremental 
improvement in model fit, χ2(1) =6.33, p=.012. With all variables in the model, AVLT 
intrusion errors significantly predicted time-to-MCI (HR: 1.04, 95% CI: 1.01–1.07, p=.008) 
along with more education (HR: 1.07, 95% CI: 1.01–1.13, p= 0.015), more functional 
difficulty (HR: 1.24, 95% CI: 1.23–1.36, p<.001), APOE ε4 carrier status (HR: 1.38, 95% 
CI: 1.03–1.85, p=.032), higher CSF t-tau levels (HR: 1.00, 95% CI: 1.00–1.01, p=.019), 
lower AVLT delayed recall (HR: 0.87, 95% CI: 0.84–0.91, p<.001), lower category fluency 
(HR: 0.93, 95% CI: 0.90–0.96, p<.001), and lower BNT (HR: 0.86, 95% CI: 0.81–0.91, p<.
001).
The three additional models examining learning slope, proactive interference, and retroactive 
interference in Block 3 showed that these process scores did not predict progression to MCI 
above and beyond the other variables included in Blocks 1 and 2 (all ps>.05). The Kaplan-
Thomas et al. Page 7
Neuropsychology. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Meier curves of intrusion errors predicting progression to MCI is shown in Figure 1. The 
overall Log Rank comparison for the categorical intrusion errors was significant, 
χ2(2)=11.43, p=.003.
The primary time-to-MCI analyses were then replicated in a follow-up series of models that 
did not include the CSF variables (p-tau, t-tau, β-amyloid), which allowed for a larger 
sample size (n=716). For Block 2, the forward stepwise procedure included the following 
variables: FAQ, APOE ε4 status, AVLT delayed recall, category fluency, BNT, and TMT 
Part B. For these analyses, the addition of intrusion errors again improved model fit, 
χ2(1)=10.31, p=.001. With all variables in the model, AVLT intrusion errors significantly 
predicted time-to-MCI (HR: 1.04, 95% CI: 1.02–1.06, p=.001). Again, learning slope, 
proactive interference, and retroactive interference in Block 3 showed that these process 
scores did not predict progression to MCI above and beyond the other variables included in 
Blocks 1 and 2 (all ps>.05).
Progression to CDR=1
Of the 525 participants included in this analysis, 22 participants progressed to a CDR score 
= 1, consistent with mild dementia, within 5 years. The results of the Cox models examining 
the predictors of time to CDR=1 are shown in Table 3. Blocks 1 and 2 (Block 1: 
demographics; Block 2: stepwise predictors) were the same across the four models. For 
Block 2, the forward stepwise procedure included the following variables: GDS, FAQ, TMT 
Part B, AVLT delayed recall, and t-tau. Blocks 1 (demographics) did not show a significant 
improvement in model fit, χ2(3)=7.73, p=.052, but Block 2 showed significant incremental 
improvement in model fit, χ2(5)=48.26, p<.001.
With the addition of intrusion errors (Block 3), there was again a significant incremental 
improvement in model fit, χ2(1)=4.68, p=.030. With all variables in the model, AVLT 
intrusion errors significantly predicted time-to-CDR=1 (HR: 1.10, 95% CI: 1.02–1.18, p=.
016), along with more depressive symptoms (HR: 1.41, 95% CI: 1.05–1.89, p=.021), more 
functional difficulty (HR: 1.61, 95% CI: 1.22–2.14, p=.001), higher CSF t-tau levels (HR: 
1.01, 95% CI: 1.01–1.02, p=.002), lower AVLT delayed recall (HR: 0.80, 95% CI: 0.68–
0.94, p=.008), and slower TMT Part B (HR: 1.02, 95% CI: 1.01–1.02, p<.001). The models 
with learning slope, proactive interference, and retroactive interference in Block 3 showed 
that these process scores did not predict progression to CDR=1 above and beyond the other 
variables included in Blocks 1 and 2 (all ps>.05). The Kaplan-Meier curves of intrusion 
errors predicting progression to CDR=1 is shown in Figure 2. The overall Log Rank 
comparison for the categorical intrusion errors was significant, χ2(2)=9.95, p=.007.
Discussion
Our results suggest that intrusion errors on the AVLT contribute unique value in predicting 
progression from cognitively normal to MCI as well as to mild dementia (CDR=1) within 5 
years. These results are significant after considering other variables shown to be important 
predictors of these outcomes for the model, including demographic characteristics (e.g., 
Chen et al., 2016; Solfrizzi et al., 2004), depressive symptoms (e.g., Palmer et al., 2007; 
Teng, Lu, & Cummings, 2007), daily functioning (Lau, Parikh, Harvey, Huang, & Farias, 
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2015; Nowrangi, Rosenberg, & Leoutsakos, 2016), vascular risk (Pase et al., 2016; Solfrizzi 
et al., 2004), genetic susceptibility (e.g., Bondi et al., 1995, 1999; Fleisher et al., 2007), CSF 
AD biomarkers (e.g., Hansson et al., 2006; Shaw et al., 2009; Sperling et al., 2011; Vemuri 
et al., 2009), and neuropsychological total scores (e.g., Blacker et al., 2007; Bondi et al., 
1999; Chen et al., 2016; DeCarli et al., 2004; Fleisher et al., 2007). After considering these 
variables for the model and inclusion of the variables that had predictive value, intrusion 
errors significantly improved the fit of the model and were a significant predictor of 
progression to MCI and progression to mild dementia. This result was also consistent when 
CSF variables were not considered in the analysis, which allowed for a larger sample size.
Evidence that intrusion errors predict clinical progression is consistent with previous work 
highlighting elevated intrusion errors in MCI (e.g., Libon et al., 2011) or non-demented 
individuals at risk for AD (due to APOE ε4 positivity or family history of AD; Bondi et al., 
1994, 1999) relative to normal control participants. It is notable that much of this prior work 
has centered on intrusion errors produced from cued-recall trials of a word list memory tests 
such as the California Verbal Learning Test (CVLT/CVLT-II) or the Philadelphia 
(repeatable) Verbal Learning Test (PrVLT; e.g., Bondi et al., 1999; Delis, Kramer, Kaplan, & 
Ober, 2000; Libon et al., 2011; Price et al., 2009); however, our findings with the AVLT 
suggest that even under free-recall conditions normal older adults produce intrusion errors 
and that these errors may be clinically meaningful. The higher frequency of intrusion errors 
made by normal participants who progressed to MCI within 5 years appears to capture 
subtle cognitive changes or inefficiencies that are not apparent in standard total 
neuropsychological test scores.
The underlying mechanism for the increased frequency of intrusion errors made by 
cognitively normal elderly who progress to MCI and/or a CDR of 1 is unclear. Previous 
investigators have speculated that elevated intrusion errors in patients with AD may be 
related to deficits in semantic memory that occur in the context of a largely intact ability to 
search through associative pathways. This search results in activation of a large number of 
irrelevant, semantically-related words that AD patients find hard to discriminate from the 
target words, and this leads to an elevation in the rate of intrusions (e.g., Fuld, 1982; Kramer 
et al., 1988). Alternatively, inefficient search and self-monitoring strategies related to frontal 
lobe deficits may be contributing to elevated intrusion errors.
Consistent with previous studies (Crocco, Curiel, Acevedo, Czaja, & Lowenstein, 2014; 
Loewenstein et al., 2004; Woodard, Dunlosky, & Salthouse, 1999), we found significant 
differences in learning slope and retroactive interference scores at baseline between stable 
normal participants and those who progressed to MCI; however, these measures did not 
significantly predict progression to MCI or mild dementia once other predictors were 
included in the models. This may be because variance was already subsumed by the large 
number of other predictors and the association between these variables and change is 
relatively weak. It is possible that changes in retroactive interference and learning slope may 
develop a stronger association with cognitive decline later in the disease process rather than 
in this early preclinical stage (up to 5 years prior to progression to MCI).
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Proactive interference scores were not significantly different in those who remained 
cognitively normal and those who progressed to MCI. This differs from previous studies that 
found increased susceptibility to proactive interference in MCI compared to normal control 
participants on a proactive semantic interference score (Crocco et al., 2014; Ebert & 
Anderson, 2009; Loewenstein et al., 2004, 2007). The difference may arise because previous 
studies, unlike the current study, used target word lists or items that were semantically 
related, used an interference list that included words/items from the same semantic 
categories as the primary list, and included cued recall conditions that might elicit intrusion 
errors (e.g., Crocco et al., 2014).
A strength of the present study is that the large sample size and wide range of variables 
made it possible to examine the added utility of memory test process scores in predicting 
progression to MCI and mild dementia after considering other known predictors of MCI and 
dementia, including genetic information and CSF biomarkers that have been used to stage 
preclinical AD (Edmonds et al., 2015a; Sperling et al., 2011). Our study is in a unique 
position to show the added value of neuropsychology, including neuropsychological process 
scores, in prediction progression from cognitively normal to MCI and mild dementia. The 
examination of neuropsychological process scores in the context of a cognitively normal 
sample that had CSF markers of AD is particularly innovative.
The three CSF biomarkers considered for inclusion in the model are those specified by Jack 
and colleagues (2016) in the Amyloid/Tau/Neurodegeneration (A/T/N) model. An incidental 
finding from the present study is that baseline CSF levels of total tau, a marker of 
neurodegeneration, emerged as the only unique CSF predictor of progression to MCI and 
mild dementia using the stepwise method. This is consistent with our previous finding from 
the ADNI sample that neurodegeneration was more likely than β-amyloid to be the first 
pathologic marker of AD in normal participants who progressed to MCI (Edmonds et al., 
2015a). It is also consistent with neuropathological evidence that abnormal tau begins to 
accumulate in the brain decades before β-amyloid in AD (Braak et al., 2011; 2013), and 
highlights the importance of adopting a definition of preclinical AD that does not require β-
amyloid to be the first stage or pathologic marker to emerge (Edmonds et al., 2015a; Jack et 
al., 2016; cf. Sperling et al., 2011).
A second incidental finding was that higher education was predictive of progression to MCI 
(though not for progression to CDR=1) when all of the variables were included in the model, 
even though there was no significant difference between the stable normal and progressed-
to-MCI groups in years of education at baseline. This finding was unanticipated and would 
need to be replicated in other samples. One possible explanation given the lack of 
relationship between education and progression to MCI in the initial, unadjusted analyses is 
that there is a suppressor effect when other predictors are added to the model, resulting in 
education predicting progression. Alternatively, this finding may reflect exhausted cognitive 
reserve in highly educated participants. The mean education within ADNI is high (16.35 
years) and further examination of the data suggested that in the context of the adjusted Cox 
model this effect may be particularly driven by individuals with graduate school education. 
Indeed, higher education may confer greater cognitive reserve (Stern et al., 1994) that allows 
an individual to accumulate more AD pathology for a given level of neuropsychological 
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performance relative to those with lower education with the same level of 
neuropsychological performance; therefore, those with higher cognitive reserve would be 
expected to progress faster (Roe, Xiong, Miller, & Morris, 2007; Stern, 2012). Thus, the 
most highly educated individuals may have entered the current study with greater pathologic 
burden than those with lower education and were no longer able to compensate for the 
accumulated pathology over the 5-year period. Further study, however, is needed to examine 
this possible education effect more comprehensively.
A potential limitation of the current study is that some of the measures used as baseline 
predictors of time to transition to MCI were also used to diagnose MCI later in the study. 
This was unavoidable given the restricted number of neuropsychological measures available 
in ADNI. This duplication presents as circularity or criterion contamination if our primary 
question was related to the predictive value of the standard neuropsychological total scores. 
However, our question was focused on the predictive value added by AVLT process scores 
that were not considered in the diagnosis of MCI. Furthermore, these MCI findings were 
replicated when a follow-up model was conducted that examined predictors of time to a 
CDR score = 1. The CDR is an independent measure that was not considered in the MCI 
diagnosis based on the neuropsychological criteria.
It is important to consider that, in general, there were a small number of intrusion errors 
made by cognitively normal participants, and similar to other variables often used to identify 
preclinical AD (e.g., Aβ1–42), the overall effect size for number of intrusion errors when 
comparing stable normal participants to progressed-to-MCI on baseline intrusion errors was 
relatively small. This finding is not surprising given the participants in this study are 
cognitively normal older adults; however, this finding may make the clinical application of 
using intrusion errors to identify preclinical AD somewhat difficult. Future work is needed 
to determine whether these intrusion errors in combination with other process scores may 
create a robust method of identifying those cognitively normal older adults at elevated risk 
for decline.
The results of the present study suggest that clinically relevant errors and subtle cognitive 
inefficiencies on word list learning and memory tests occur in older adults who are 
cognitively normal according to standard neuropsychological total test scores. These subtle 
changes may contribute to the ability to predict the subsequent development of MCI and AD 
in older adults. Importantly, intrusion errors predicted progression to MCI and mild 
dementia even after considering AD CSF biomarkers that make up the working definition of 
preclinical AD (Sperling et al., 2011) as well as other known risk factors, thus highlighting 
the importance of neuropsychological assessment that considers more that 
neuropsychological total scores. Future work should continue to examine the role of process 
scores on memory and other cognitive tests as tools to improve diagnostic and predictive 
accuracy for preclinical AD.
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Public Significance Statement
The results of this study show the added value of memory word-list intrusion errors in 
predicting cognitively normal older adults’ progression to mild cognitive impairment 
after accounting for a large number of other factors known to predict progression to 
Alzheimer’s disease. Using neuropsychological process/error scores may allow for earlier 
detection of subtle cognitive changes or cognitive inefficiencies that have not yet emerged 
as clinical impairments on neuropsychological testing. Reliable identification of persons 
at risk for cognitive decline would allow for greater opportunity to intervene earlier to 
prevent or delay future decline.
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Figure 1. 
Kaplan-Meier estimates of the rate of progression from cognitively normal to MCI (220 
participants out of 525 progressed within 5 years) by number of baseline intrusion errors. 
Intrusion error categories were based on >1 SD below the mean (0 errors), −1 to +1 SD (1–7 
errors) and >1 SD above the mean (8+ errors) of the error score distribution.
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Figure 2. 
Kaplan-Meier estimates of the rate of progression from cognitively normal to CDR=1 (22 
participants out of 525 progressed within 5 years) by number of baseline intrusion errors. 
Intrusion error categories were based on >1 SD below the mean (0 errors), −1 to +1 SD (1–7 
errors) and >1 SD above the mean (8+ errors) of the error score distribution.
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